Literature DB >> 11340636

Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array.

A Chetcuti1, S Margan, S Mann, P Russell, D Handelsman, J Rogers, Q Dong.   

Abstract

BACKGROUND: To understand the molecular mechanisms underlying prostate cancer, we have utilized the gene expression array to search for genes whose expression is altered in this disease.
METHODS: RNA quality from manual microdissected tissue was compared with that from microselected tissue by electrophoresis. For array analysis, malignant and normal prostate epithelium was enriched using microselection technique from prostate cancer and the peripheral zone of a normal prostate. Identical array membrane was hybridized to labeled cancer and normal cDNA, respectively. The differentially expressed gene was further evaluated by RT-PCR.
RESULTS: Microdissection, but not microselection, causes visible degradation to RNA. Of the 588 genes on the membrane, 87 genes yielded significant signals. Based on a three fold difference relative to normal prostate tissue, 1 gene was overexpressed and 12 genes underexpressed in prostate cancer. Of them, five showed statistically significant reduction in mRNA levels in six prostate cancer specimens compared with seven normal prostate specimens. These five genes are glutathione S-transferase M1 (GSTM1), monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-alpha receptor-1 (TNFR-1), transforming growth factor beta3 (TGF-beta3), and inhibitor of DNA binding-1 (ID-1).
CONCLUSIONS: GST-based metabolism, cytokine MCP-1 and TNFR-1, and TGF-beta3 signaling pathways, and some helix-loop-helix nuclear proteins could be potentially important in organ-confined prostate cancer and deserve further investigation. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11340636     DOI: 10.1002/pros.1056

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  22 in total

Review 1.  Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic.

Authors:  Jian Zhang; Lalit Patel; Kenneth J Pienta
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

2.  Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy.

Authors:  Andrew J Stephenson; Alex Smith; Michael W Kattan; Jaya Satagopan; Victor E Reuter; Peter T Scardino; William L Gerald
Journal:  Cancer       Date:  2005-07-15       Impact factor: 6.860

3.  Monocyte chemotactic protein-1 and CC chemokine receptor 2 polymorphisms and prognosis of renal cell carcinoma.

Authors:  Guan-Xian Liu; Xin Zhang; Su Li; Richard D Koiiche; Jerry H Sindsceii; Haihan Song
Journal:  Tumour Biol       Date:  2013-05-09

4.  Genetic variants of chemokine CCL2 and chemokine receptor CCR2 genes and risk of prostate cancer.

Authors:  Raju K Mandal; Toshi Agrawal; Rama Devi Mittal
Journal:  Tumour Biol       Date:  2014-09-30

5.  Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process.

Authors:  Uma R Chandran; Changqing Ma; Rajiv Dhir; Michelle Bisceglia; Maureen Lyons-Weiler; Wenjing Liang; George Michalopoulos; Michael Becich; Federico A Monzon
Journal:  BMC Cancer       Date:  2007-04-12       Impact factor: 4.430

6.  PTOV-1, a novel protein overexpressed in prostate cancer, shuttles between the cytoplasm and the nucleus and promotes entry into the S phase of the cell division cycle.

Authors:  Anna Santamaría; Pedro L Fernández; Xavier Farré; Patricia Benedit; Jaume Reventós; Juan Morote; Rosanna Paciucci; Timothy M Thomson
Journal:  Am J Pathol       Date:  2003-03       Impact factor: 4.307

7.  Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia.

Authors:  Kazutoshi Fujita; Charles M Ewing; Robert H Getzenberg; J Kellogg Parsons; William B Isaacs; Christian P Pavlovich
Journal:  Prostate       Date:  2010-04-01       Impact factor: 4.104

8.  LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer.

Authors:  Tammy L Romanuik; Gang Wang; Olena Morozova; Allen Delaney; Marco A Marra; Marianne D Sadar
Journal:  BMC Med Genomics       Date:  2010-09-24       Impact factor: 3.063

Review 9.  TGF-beta3 and cancer: a review.

Authors:  H G Laverty; L M Wakefield; N L Occleston; S O'Kane; M W J Ferguson
Journal:  Cytokine Growth Factor Rev       Date:  2009-08-04       Impact factor: 7.638

10.  Inhibitor of DNA binding-1 overexpression in prostate cancer: relevance to tumor differentiation.

Authors:  Xiaoling Yu; Xiaohui Xu; Baojian Han; Rongxiang Zhou
Journal:  Pathol Oncol Res       Date:  2008-08-28       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.